Dual-modality FDG-PET/CT in follow-up of patients with recurrent iodine-negative differentiated thyroid cancer

European Radiology

Volumn 17, Issue 12, 2007, Pages 3139-3147

  Freudenberg, Lutz S ^a   Frilling, Andrea ^a   Kühl, Hilmar ^a   Müller, Stefan P ^a   Jentzen, Walter ^a   Bockisch, Andreas ^a   Antoch, Gerald ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Differentiated thyroid cancer; Dual modality; FDG; PET CT

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IOBITRIDOL; IODINE; IODINE 131; LEVOTHYROXINE;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; LUNG METASTASIS; MALE; PATIENT CARE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; THYROID CANCER;

ADULT; AGED; AGED, 80 AND OVER; CONFIDENCE INTERVALS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS;

EID: 36349035982     PISSN: 09387994     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00330-007-0682-2     Document Type: Article

References (37)

1. Gilliland FD, Hunt WC, Morris DM et al (1997) Prognostic factors for thyroid carcinoma: A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991. Cancer 79:564-573
2. Schlumberger MJ (1999) Diagnostic follow-up of well-differentiated thyroid carcinoma: Historical perspective and current status. J Endocrinol Invest 22(11 Suppl):3-7
3. Maxon HR (1999) Quantitative radioiodine therapy in the treatment of differentiated thyroid cancer. Q J Nucl Med 43:313-323
4. Schlumberger MJ (1998) Papillary and follicular thyroid carcinoma. N Engl J Med 338:297-306
5. Frilling A, Gorges R, Tecklenborg K et al (2000) Value of preoperative diagnostic modalities in patients with recurrent thyroid carcinoma. Surgery 128:1067-1074
6. Grunwald F, Schomburg A, Bender H et al (1996) Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 23:312-319
7. Stokkel MP, Duchateau CS, Dragoiescu C (2006) The value of FDG-PET in the follow-up of differentiated thyroid cancer: A review of the literature. Q J Nucl Med Mol Imaging 50:78-87
8. Grünwald F, Kalicke T, Feine U et al (1999) Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med 26:1547-1552
9. Wang W, Macapinlac H, Larson SM et al (1999) [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic 131I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 84:2291-2302
10. Scott GC, Meier DA, Dickinson CZ (1995) Cervical lymph node metastasis of thyroid papillary carcinoma imaged with fluorine-18-FDG, technetium-99 m pertechnetate and iodine-131-sodium iodide. J Nucl Med 36:1843-1845
11. Chung JK, So Y, Lee JS et al (1999) Value of FDG PET in papillary thyroid carcinoma with negative I-131 whole-body scan. J Nucl Med 40:986-992
12. Feine U, Lietzenmayer R, Hanke JP et al (1996) Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med 37:1468-1472
13. Weber WA, Avril N, Schwaiger M (1999) Relevance of positron emission tomography (PET) in oncology. Strahlenther Onkol 175:356-373
14. Schmidt GP, Schoenberg SO, Schmid R, Stahl R, Tiling R, Becker CR, Reiser MF, Baur-Melnyk A (2007) Screening for bone metastases: whole-body MRI using a 32-channel system versus dual-modality PET-CT. Eur Radiol 17:939-949
15. Veit P, Antoch G, Stergar H, Bockisch A, Forsting M, Kuehl H (2006) Detection of residual tumor after radiofrequency ablation of liver metastasis with dual-modality PET/CT: Initial results. Eur Radiol 16:80-87
16. Wahl RL, Quint LE, Cieslak RD et al (1993) "Anatometabolic" tumor imaging: Fusion of FDG PET with CT or MRI to localize foci of increased activity. J Nucl Med 34:1190-1197
17. Freudenberg LS, Fischer M, Antoch G, Jentzen W, Gutzeit A, Rosenbaum SJ, Bockisch A, Egelhof T (2005) Dual modality of 18F-fluorodeoxyglucose-positron emission tomography/computed tomography in patients with cervical carcinoma of unknown primary. Med Princ Pract 14:155-160
18. Palmedo H, Bucerius J, Joe A, Strunk H, Hortling N, Meyka S, Roedel R, Wolff M, Wardelmann E, Biersack HJ, Jaeger U (2006) Integrated PET/CT in differentiated thyroid cancer: Diagnostic accuracy and impact on patient management. J Nucl Med 47:616-624
19. Zimmer LA, McCook B, Meltzer C, Fukui M, Bascom D, Snyderman C, Townsend DW, Johnson JT (2003) Combined positron emission tomography/computed tomography imaging of recurrent thyroid cancer. Otolaryngol Head Neck Surg 128:178-184
20. Nahas Z, Goldenberg D, Fakhry C, Ewertz M, Zeiger M, Ladenson PW, Wahl R, Tufano RP (2005) The role of positron emission tomography/computed tomography in the management of recurrent papillary thyroid carcinoma. Laryngoscope 115:237-243
21. Saab G, Driedger AA, Pavlosky W, McDonald T, Wong CY, Yoo J, Urbain JL (2006) Thyroid-stimulating hormone-stimulated fused positron emission tomography/computed tomography in the evaluation of recurrence in 131I-negative papillary thyroid carcinoma. Thyroid 16:267-272
22. Ong SC, Ng DC, Sundram FX (2005) Initial experience in use of fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography in thyroid carcinoma patients with elevated serum thyroglobulin but negative iodine-131 whole body scans. Singapore Med J 46:297-301
23. Fleming ID, Cooper JS, Henson DE (eds) (1997) AJCC cancer staging manual. 5th edn. American Joint Committee on Cancer. Lippincott-Raven, Philadelphia
24. Beyer T, Antoch G, Müller S, Egelhof T, Freudenberg LS, Debatin J, Bockisch A (2004) Protocol considerations for combined PET/CT imaging. J Nucl Med 45(suppl 1):25S-35S
25. Antoch G, Jentzen W, Freudenberg LS, Stattaus J, Mueller SP, Debatin JF, Bockisch A (2003) Effect of oral contrast agents on computed tomography-based positron emission tomography attenuation correction in dual-modality positron emission tomography/computed tomography imaging. Invest Radiol 38:784-789
26. Brown LD, Cai TT, DasGupta A (2001) Interval estimation for a Binomial proportion. Stat Sci 16:101-133
27. Nanni C, Rubello D, Fanti S, Farsad M, Ambrosini V, Rampin L, Banti E, Carpi A, Muzzio P, Franchi R (2006) Role of 18F-FDG-PET and PET/CT imaging in thyroid cancer. Biomed Pharmacother 60:409-413
28. do Rosario PW, de Faria S, Bicalho L et al (2005) Ultrasonographic differentiation between metastatic and benign lymph nodes in patients with papillary thyroid carcinoma. J Ultrasound Med 24:1385-1389
29. van den Brekel MW, Stel HV, Castelijns JA et al (1990) Cervical lymph node metastasis: Assessment of radiological criteria. Radiology 177:379-384
30. Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME (2001) A tabulated summary of the FDG PET literature. J Nucl Med 42:1S-93S
31. Buell U, Wieres FJ, Schneider W, Reinartz P (2004) 18FDG-PET in 733 consecutive patients with or without side-by-side CT evaluation: Analysis of 921 lesions. Nuklearmedizin 43:210-216
32. Truong MT, Erasmus JJ, Munden RF, Marom EM, Sabloff BS, Gladish GW, Podoloff DA, Macapinlac HA (2004) Focal FDG uptake in mediastinal brown fat mimicking malignancy: A potential pitfall resolved on PET/CT. AJR Am J Roentgenol 183:1127-1132
33. Hany TF, Gharehpapagh E, Kamel EM, Buck A, Himms-Hagen J, von Schulthess GK (2002) Brown adipose tissue: A factor to consider in symmetrical tracer uptake in the neck and upper chest region. Eur J Nucl Med Mol Imaging 29:1393-1398
34. Rosenbaum SJ, Lind T, Antoch G, Bockisch A (2006) False-positive FDG PET uptake - the role of PET/CT. Eur Radiol 16:1054-1065
35. Sisson JC, Ackermann RJ, Meyer MA et al (1993) Uptake of 18-fluoro-2-deoxy-D-glucose by thyroid cancer: Implications for diagnosis and therapy. J Clin Endocrinol Metab 77:1090-1094
36. Bockisch A, Beyer T, Antoch G, Freudenberg LS, Kuhl H, Debatin JF, Muller SP (2004) Positron emission tomography/computed tomography-imaging protocols, artifacts, and pitfalls. Mol Imaging Biol 6:188-199
37. Kassenärztliche Bundesvereinigung: Richtlinien des Bundesausschusses der Ärzte und Krankenkassen über Kriterien zur Qualitätsbeurteilung in der radiologischen Diagnostik gemäß § 136 SGB V in der Fassung vom 17. Juni 1992 (veröffentlicht im Bundesanzeiger Nr. 183 b vom 29. September 1992), zuletzt geändert am 17. Dezember 1996 (veröffentlicht im Bundesanzeiger Nr. 49 vom 12. März 1997). Deutsches Ärzteblatt 1997; 94, A779-A787